Yizhe Wang

Dr. Wang most recently served as Global Brand Development Leader, Eli Lilly Oncology. In 2020, Dr. Wang served as Global Platform Lead for anti-COVID Therapy, Lilly Research Lab, where he led a new operating model integrating discovery, development, and launch resulting in the EUA of bamlanivimab. Previously, Dr. Wang was SVP, Head of BioMedicines and Oncology Businesses, Lilly China, where he was a member of the Global Oncology and Biomedicines Business Unit lead teams, and China Executive Committee. In this role, he oversaw a 1,000-person organization, delivered double-digit sales growth, and launched multiple new products, including Tyvyt, Elunate, Taltz, and Olumiant. Prior to Eli Lilly, Dr. Wang was at GSK for 15 years where he held product and commercial strategy roles of increasing responsibility in the U.S. (2003-2012), U.K. (2012-2014), and China (2014-2018), ultimately serving as Head of GSK China Pharmaceuticals’ Respiratory Business Unit. Earlier in his career, he was a researcher at Bristol Myers Squibb. Dr. Wang received a doctorate in organic chemistry from Yale University. He also earned a master’s degree in business administration from the Wharton School at the University of Pennsylvania and a bachelor’s degree in chemistry from Ramapo College of New Jersey.